What we do
The Henderson lab is interested in the cellular and molecular mechanisms that drive organ fibrosis, and also the molecular pathways which are responsible for efficient wound healing and healthy tissue regeneration following injury.
Single-cell genomics approaches are transforming our understanding of disease pathogenesis, allowing interrogation of homeostatic and pathogenic cell populations at unprecedented resolution, and adding an illuminating dimension to transcriptomic information relative to traditional methods that profile bulk cell populations. The single cell genomics field has developed rapidly over the last few years, chiefly because these approaches allow powerful, unbiased exploration of cell states and types at single-cell resolution, resulting in unexpected novel insights into tissue biology and disease mechanisms.
Why we do it
Organ fibrosis (scarring) is a major cause of morbidity and mortality worldwide, and as yet there are no effective anti-fibrotic treatments. By understanding more about how organs scar, heal and regenerate we hope to develop new treatments for patients with organ fibrosis.
The convergence of these multi-modal single-cell technologies represent a remarkable opportunity to decode the molecular mechanisms regulating human tissue fibrosis and regeneration at single cell resolution, which we hope will inform and accelerate the development of effective new therapies for patients with fibrotic diseases.
|Jul 14, 2023||The Hendo lab welcomes Triin Ounapuu, Hannah Barron and Pedro Arede Rei as a new Research Assistants in the group!|
|Oct 9, 2022||Laura Kitto (Wellcome Trust ECAT Clinical PhD student in our lab) has won best oral presentation at the United European Gastroenterology meeting in Vienna for her work on the role of hepatic stellate cells in acute liver injury – congratulations Laura!!|
|Sep 1, 2022||The Hendo lab welcomes Rowena Hosie as a new Research Assistant in the group!|
|Aug 1, 2022||The Hendo lab welcomes Aymara Mullen as a new Research Assistant in the group!|
|Aug 1, 2022||The Henderson Lab website has gone live!|
- NatureFibrosis: from mechanisms to medicinesNature 2020
Fibrosis can affect any organ and is responsible for up to 45% of all deaths in the industrialized world. It has long been thought to be relentlessly progressive and irreversible, but both preclinical models and clinical trials in various organ systems have shown that fibrosis is a highly dynamic process. This has clear implications for therapeutic interventions that are designed to capitalize on this inherent plasticity. However, despite substantial progress in our understanding of the pathobiology of fibrosis, a translational gap remains between the identification of putative antifibrotic targets and conversion of this knowledge into effective treatments in humans. Here we discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.
- NatureResolving the fibrotic niche of human liver cirrhosis at single-cell levelNature 2019
Liver cirrhosis is a major cause of death worldwide and is characterized by extensive fibrosis. There are currently no effective antifibrotic therapies available. To obtain a better understanding of the cellular and molecular mechanisms involved in disease pathogenesis and enable the discovery of therapeutic targets, here we profile the transcriptomes of more than 100,000 single human cells, yielding molecular definitions for non-parenchymal cell types that are found in healthy and cirrhotic human liver. We identify a scar-associated TREM2+CD9+ subpopulation of macrophages, which expands in liver fibrosis, differentiates from circulating monocytes and is pro-fibrogenic. We also define ACKR1+ and PLVAP+ endothelial cells that expand in cirrhosis, are topographically restricted to the fibrotic niche and enhance the transmigration of leucocytes. Multi-lineage modelling of ligand and receptor interactions between the scar-associated macrophages, endothelial cells and PDGFRα+ collagen-producing mesenchymal cells reveals intra-scar activity of several pro-fibrogenic pathways including TNFRSF12A, PDGFR and NOTCH signalling. Our work dissects unanticipated aspects of the cellular and molecular basis of human organ fibrosis at a single-cell level, and provides a conceptual framework for the discovery of rational therapeutic targets in liver cirrhosis.
- CellRepSingle-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosisCell reports 2019
Iterative liver injury results in progressive fibrosis disrupting hepatic architecture, regeneration potential, and liver function. Hepatic stellate cells (HSCs) are a major source of pathological matrix during fibrosis and are thought to be a functionally homogeneous population. Here, we use single-cell RNA sequencing to deconvolve the hepatic mesenchyme in healthy and fibrotic mouse liver, revealing spatial zonation of HSCs across the hepatic lobule. Furthermore, we show that HSCs partition into topographically diametric lobule regions, designated portal vein-associated HSCs (PaHSCs) and central vein-associated HSCs (CaHSCs). Importantly we uncover functional zonation, identifying CaHSCs as the dominant pathogenic collagen-producing cells in a mouse model of centrilobular fibrosis. Finally, we identify LPAR1 as a therapeutic target on collagen-producing CaHSCs, demonstrating that blockade of LPAR1 inhibits liver fibrosis in a rodent NASH model. Taken together, our work illustrates the power of single-cell transcriptomics to resolve the key collagen-producing cells driving liver fibrosis with high precision.